Journal Article

Outcomes of allogeneic hematopoietic cell transplantation under letermovir prophylaxis for cytomegalovirus infection

Fuji, Shigeo, Seo, Sachiko, Kobayashi, Takeshi, Tanaka, Masatsugu, Takenaka, Katsuto, Kimura, Takafumi, Nakasone, Hideki, Ikegame, Kazuhiro, Ogata, Masao, Atsuta, Yoshiko, Matsukawa, Toshihiro, Ozawa, Yukiyasu, Nakamae, Hirohisa, Sawa, Masashi, Kanda, Yoshinobu, Maruyama, Yumiko, Ara, Takahide, Uchida, Naoyuki, Fukuda, Takahiro, Matsuo, Keitaro

2024

Overview

Cytomegalovirus (CMV) infection is a major infectious complication following allogeneic hematopoietic cell transplantation (allo-HCT). Although letermovir (LMV) prophylaxis dramatically reduces the incidence of early clinically significant CMV (csCMV) infection, it remains unclear whether it has a beneficial effect on nonrelapse mortality (NRM) and overall survival (OS). Herein, we evaluated the impact of LMV prophylaxis on posttransplant outcomes using the registry database of the Japanese Society for Transplantation and Cellular Therapy. Adult patients who underwent allo-HCT between 2017 and 2019 were analyzed (n = 6004). LMV prophylaxis was administered to 1640 patients (LMV group) and it significantly reduced the incidence of csCMV infection compared with those not administered LMV prophylaxis (15.4% vs 54.1%; p < 0.01). However, it did not improve the 1-year NRM (hazard ratio [HR], 0.93; p = 0.40) and OS (HR, 0.96; p = 0.49). In the LMV group, 74 patients had breakthrough csCMV infection and showed inferior NRM (HR, 3.44; p < 0.01) and OS (HR, 1.93; p = 0.02) compared with those without infection. After completing LMV prophylaxis, 252 patients had late csCMV infection and showed inferior NRM (HR, 1.83; p < 0.01) and OS (HR, 1.58; p < 0.01). Our findings suggest that managing breakthrough and late csCMV infections is important for improving long-term outcomes.

• Publisher: Springer Nature B.V
• Subject: Antiviral drugs / Cytomegalovirus / Disease prevention / Infections / Stem cell transplantation